Figure 2 | British Journal of Cancer

Figure 2

From: Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer

Figure 2

Cumulative survival of patients based on baseline CA19-9 level (A) and objective response (B). The median survival time of patients with baseline CA19-9 level less than 1000 U ml−1 and more than 1000 U ml−1 were 20.1 and 8.2 months, respectively. The median survival time of patients with objective response (CR+PR), SD, and PD were 18.3, 16.7, and 7.5 months, respectively.

Back to article page